Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis

Leukemia Research

Volumn 28, Issue SUPPL. 1, 2004, Pages

  Ishii, Yuko ^a   Ito, Yoshikazu ^a   Kuriyama, Yuzuru ^a   Tauchi, Tetsuzo ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HYDROXYUREA; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISOLONE; RECOMBINANT ALPHA INTERFERON;

ADULT; ANAMNESIS; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; CYTOGENETICS; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HYPEREOSINOPHILIC SYNDROME; LABORATORY TEST; LETTER; LUNG LAVAGE; MALE; MYELOFIBROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 1342343032     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00179-6     Document Type: Letter

References (9)

1. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571* a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932.
2. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J.et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. New Engl. J. Med. 347:2002;481-487.
3. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., Butterfield J.H. Treatment of hypereosinophilic syndrome. Lancet. 359:2002;1577-1578.
4. Ault P., Cortes J., Koller C., Kaled E.S., Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk. Res. 26:2002;881-884.
5. Schaller J.L., Burkland G.A. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med. Gen. Med. 3:2001;9.
6. Pardanani A.D., Reeder T.L., Porrata L.F., Li C.Y., Tazelaar H.D., Baxter E.J.et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 101:2003;3391-3397.
7. World Health Organization classification of tumors. Pathology and genetics, tumor of haematopoietic and lymphoid tissues. Jaffe WRC Press; 2001.
8. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J. et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New Engl. J. Med. 348:2003;1201-1214.
9. Bach M.K., Brashler J.R., Stout B.K., Johnson H.G., Sanders M.E., Lin A.H. Activation of human eosinophils by platelet-derived growth factor. Int. Arch. Allergy Immunol. 97:1992;121-129.